Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - last conversion of Bracknor financing programme

FIT Biotech Oy
Posted on: 26 Feb 18

FIT Biotech Oy

Company release February 26, 2018 at 5:30 PM EET

Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - last conversion of Bracknor financing programme

Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company's Board of Directors has resolved on February 26, 2018 to approve Bracknor's request relating to the funding programme to convert EUR 380,000 worth of Convertible Capital Notes into the Company's K shares.

Due to the conversion of the Convertible Capital Notes, the Company transfers 194,373,400 new K shares in the Company to Bracknor with the conversion price of EUR 0.001955 per share and the share capital of the Company will be increased by EUR 380,000.00. The Board authorization is based on the Extraordinary General Meeting of December 14, 2017.

The K shares will be admitted to trading on First North Finland as soon as possible.

After this transaction FIT Biotech Oy has listed shares amounting to 577,209,430 K shares.

After the conversion of these Convertible Capital Notes, Bracknor does not have Convertible Capital Notes left to convert.


Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

Principal media

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: FIT Biotech Oy via GlobeNewswire

Last updated on: 27/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.